YPN-067

YPN-067 is an investigational small molecule drug candidate developed by Yungjin Pharma, currently in Phase 2 clinical development. The compound is characterized by a dual or ambiguous therapeutic focus in company pipeline documentation; while it is frequently categorized under oncology sections, it is explicitly flagged for respiratory indications, specifically Chronic Obstructive Pulmonary Disease (COPD). As a member of the 'YPN' series (Yungjin Pharma New-chemical-entity), it is likely a synthetic small molecule, distinguishing it from the company's botanical respiratory lead, YPL-001. Specific details regarding its molecular target and mechanism of action have not been widely disclosed in public clinical databases, although its Phase 2 status suggests it is a significant mid-stage asset in Yungjin's portfolio.